Back to top
more

Eyenovia (EYEN)

(Delayed Data from NSDQ)

$0.58 USD

0.58
769,189

+0.04 (7.54%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.58 0.00 (-0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eyenovia (EYEN) Down 18% on Disappointing Corporate Update

by Zacks Equity Research

Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.

Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of -5.88% and 99.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

by Ekta Bagri

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of 11.54% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.

Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.

Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY

by Zacks Equity Research

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Regeneron (REGN), among others.

Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.

Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.

Bausch Acquires License for Myopia Solution from Eyenovia

by Zacks Equity Research

Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.

Will Eyenovia Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Eyenovia

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.

Eyenovia, Inc. (EYEN) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).

All You Need to Know About Eyenovia, Inc. (EYEN) Rating Upgrade to Strong Buy

by Zacks Equity Research

Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Can European Buyouts Aid Canopy Growth's (CGC) Q2 Earnings?

by Zacks Equity Research

Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.

What's in Store for Applied Materials' (AMAT) Q4 Earnings?

by Zacks Equity Research

Applied Materials' (AMAT) technology leadership position and strong product line in Display and Services are likely to reflect on fiscal fourth-quarter results.

Can Cannabis Therapy Drive Canopy Growth's (CGC) Q2 Earnings?

by Zacks Equity Research

A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.

Overstock (OSTK) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Overstock's (OSTK) third-quarter results are likely to reflect strength across retail and blockchain businesses.

Kinjel Shah headshot

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

by Kinjel Shah

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Cronos (CRON) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress, when it reports Q3 results.

Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2019 results.

Mettler-Toledo (MTD) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Mettler-Toledo's (MTD) third-quarter results are likely to reflect strength across Laboratory and Industrial segments.

CannTrust (CTST) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.